BEDFORD, Mass. (AP) _ Homology Medicines Inc. (FIXX) on Thursday reported a loss of $24.2 million in its fourth quarter.
The Bedford, Massachusetts-based company said it had a loss of 55 cents per share.
The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 72 cents per share.
The gene editing company posted revenue of $563,000 in the period.
For the year, the company reported that its loss widened to $103.9 million, or $2.47 per share. Revenue was reported as $1.7 million.
Homology Medicines shares have declined 32% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $14.06, a decline of 46% in the last 12 months.